Objective
To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.
Management group
Launch date
29/10/2019
Domicile
Guernsey
Fund manager
Naveen Yalamanchi, Roderick Wong, Woody Stileman, Oliver Kenyon
Dividend frequency
N/A
Wind-up provisions
The Company has an unlimited life.
Market Cap (m) Total assets (m) Price (last close) NAV Discount / premium (%) Gearing (%) Dividend yield (%) Dividend dates Ongoing charge (%)
786.46 921.84 2.44 2.86 -14.69 0 0.00 N/A 1.74 (31/12/2025)
Scroll

Dividends

Dividends declared in last 12 months

There have been no dividends in the last 12 months.

Performance (%)

Return type 1 year 3 years 5 years 10 years
RTW Biotech Opportunities Share price total return 86.2 82.7 18.0 N/A
Healthcare & Biotechnology AIC sector Share price total return 37.2 20.3 -1.5 96.7
Scroll

Share structure

Number of shares
322,321,264

Traded volumes (number of shares)

  Yesterday 1 month 1 year 5 years
Total 55,231 12,001,779 184,145,345 417,597,213
Average N/A 571,513 727,847 331,164
Scroll

Traded values (m)

  Yesterday 1 month 1 year 5 years
Total 0.13 28.31 346.47 664.20
Average N/A 1.35 1.37 0.53
Scroll

Trading details

ISIN Ticker Traded currency Stock exchange
GG00BKTRRM22 RTW USD London Stock Exchange - MAIN
Chi-x Europe Limited
London Stock Exchange
Scroll

Top holdings

Data as at : 31/12/2025

Investment % of total assets
Other Assets 22.6
Ptct 12.9
CORXEL Pharmaceuticals 6.2
Stok 5.2
Urgn 5.0
Insm 3.9
Kailera Therapeutics 3.4
Tars 2.8
Imtx 2.7
Argx 2.2

Morningstar logo Data provided by Morningstar.

FE fundinfo logo Company documents provided by FE fundinfo.